Thyrocare Technologies Limited announced that its promoter, Docon Technologies Private Limited, has sold 1,57,69,696 equity shares. This transaction, representing approximately 9.90% of the company’s paid-up equity share capital, reduced Docon’s holding from 60.92% to 51.02%. The sale was conducted through market trades on August 13, 2026, with settlements in accordance with applicable regulations.
Promoter Sells Significant Equity Stake
Thyrocare Technologies Limited has disclosed a substantial transaction involving its promoter, Docon Technologies Private Limited. Docon has divested a total of 1,57,69,696 equity shares in Thyrocare through open market trades on August 13, 2026. This sale marks a significant change in the promoter’s shareholding structure within the company.
Shareholding Impact
The disposed shares represent approximately 9.90% of the total paid-up equity share capital of Thyrocare Technologies Limited. Consequently, the promoter’s overall shareholding in the company has seen a reduction from 60.92% to 51.02%. Despite this sale, Docon Technologies Private Limited continues to be recognized as a promoter and a holding entity of Thyrocare.
Transaction Details
The settlement for this transaction will be processed in compliance with all prevailing laws and regulatory frameworks. Thyrocare Technologies Limited has formally informed the stock exchanges regarding this disclosure from its promoter.
Source: BSE
